People · Operator

Barbara Cannon

Named in public records as an officer, director or promoter · active 2015–2021 · Healthtech, Pharmaceuticals

2
Companies
5
Filings
$16.7M
Combined raised · real
Serial
Operator type
Companies
CompanyRoleSectorStageRaised · realValue · estTied
Reimagine Care, Inc.HealthtechSeries A$8.7M$7.2M2021
NuSirt Sciences Inc.PharmaceuticalsSeries A$8.1M$61.9M2015
Operator network

Barbara Cannon at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.

Devin Carty · 10 companies · 1 sharedDevin CartyDouglas French · 4 companies · 1 sharedDouglas FrenchKeith Figlioli · 4 companies · 1 sharedKeith FiglioliChris Stenzel · 2 companies · 1 sharedChris StenzelFeby Abraham · 2 companies · 1 sharedFeby AbrahamAaron Gerber · 1 companies · 1 sharedAaron GerberDan Nardi · 1 companies · 1 sharedDan NardiHarlan Levine · 1 companies · 1 sharedHarlan LevineJOSEPH C. COOK, JR. · 5 companies · 1 sharedJOSEPH C. COOK, J…Brian C. Laden · 1 companies · 1 sharedBrian C. LadenEric C. Satz · 1 companies · 1 sharedEric C. SatzMichael C. Zemel · 1 companies · 1 sharedMichael C. ZemelVaughn C. Bryson · 1 companies · 1 sharedVaughn C. BrysonReimagine Care, Inc. · $8.7M raisedReimagine Care, Inc.NuSirt Sciences Inc. · $8.1M raisedNuSirt Sciences Inc.Barbara CannonBC
Barbara Cannon Company Co-operator (ring = serial)Hover to isolate ties · click to open
Co-operators (shared boards)

People named alongside Barbara Cannon on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.

OperatorSharedTheir companies
Devin Carty110
JOSEPH C. COOK, JR.15
Douglas French14
Keith Figlioli14
Chris Stenzel12
Feby Abraham12
Brian C. Laden11
Dan Nardi11
Aaron Gerber11
Harlan Levine11
Eric C. Satz11
Vaughn C. Bryson11
Michael C. Zemel11

People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.